glp-1 ed Your Game Plan GLP-1 | Summary

Payer coverage of GLP-1s is restricted and limited today Today, commercial coverage of GLP-1s is limited and government coverage of GLP-1s is off-limits for weight loss

Careful balancing of polyagonist efficacy against safety, alongside early-phase monitoring for neuropsychiatric outcomes, will be essential in developing these agents for addiction

Determining the optimal zone for organellar proximity will require dose- and kinetics-aware strategies guided by real-time biomarkers

Gutzwiller J.-P., Drewe J., Goke B., et al

doi: 10.1038/s41574-018-0048-7 [DOI] [PMC free article] [PubMed] [Google Scholar] 12.Luchsinger JA